ACOG

Quest's QHerit will screen for 22 disorders and is based on recommendations issued this year by the American College of Obstetricians and Gynecologists.

The company announced the new product, which covers variants across 600 genes, this week, and said it will be available to customers next month.

The ob-gyn groups issued a statement warning that insurers' prior authorization requirements will hinder patients' access to much needed care.

"Conventional screening methods remain the most appropriate choice for first-line screening for most women in the general obstetric population," the committee wrote.

This article has been updated to include comments from CytoGenX.
CytoGenX, a Stony Brook, NY-based medical genetic testing services company, recently introduced chromosomal microarray analysis for a number of different indications.

Counsyl has begun offering a next-generation sequencing-based expanded carrier screening test to early access users with a full commercial launch planned for the end of the second quarter this year.

It remains to be seen whether a market for PCR-based fragile X population screening will soon develop, since mandating newborn testing may be highly dependent on the development of a difference-making therapeutic; and carrier screening will likely continue to rely on a case-by-case cost-benefit analysis.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.